# Agrylin Drug Use-Result Survey

> **NCT03625895** · — · COMPLETED · sponsor: **Takeda** · enrollment: 1826 (actual)

## Conditions studied

- Essential Thrombocythemia (ET)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03625895
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-25
- **Primary completion:** 2021-03-11
- **Final completion:** 2021-03-11
- **Target enrollment:** 1826 (ACTUAL)
- **Last updated:** 2023-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03625895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03625895, "Agrylin Drug Use-Result Survey". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03625895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*